ADO 0.00% 2.1¢ anteotech ltd

Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-21

  1. 3,054 Posts.
    lightbulb Created with Sketch. 567
    Ironically we haven't lost any sales and it was always reported as a Q2 2023 target for the common list approvals... Not sure how the share price will react, but imo should highlight that we have the right CEO now and with some gusto.


 
watchlist Created with Sketch. Add ADO (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.